Differential CD8+FoxP3+T Cell Infiltration Patterns Associate with Pathologic Response after Neoadjuvant Anti-PD-1 in NSCLC

被引：0

作者：

Fotheringham, M. ^{[1
]}

Green, B. ^{[2
]}

Roskes, J. S. ^{[2
]}

Cohen, E. ^{[1
]}

Zhang, B. ^{[2
]}

Engle, L. L. ^{[2
]}

Wang, D. ^{[2
]}

Jimenez-Sanchez, D. ^{[2
]}

Caushi, J. X. ^{[2
]}

Zhang, J. ^{[2
]}

D'Amiano, N. ^{[2
]}

Sunshine, J. C. ^{[2
]}

Deutsch, J. S. ^{[2
]}

Uttam, S. ^{[1
]}

Fiorante, A. ^{[1
]}

Espinosa, N. A. ^{[1
]}

Popa, T. ^{[1
]}

Ogurtsova, A. ^{[2
]}

Soto-Diaz, S. ^{[2
]}

Eminizer, M. ^{[2
]}

Medvedev, D. ^{[2
]}

Chaft, J. E. ^{[3
]}

Brahmer, J. R. ^{[2
]}

Conroy, M. ^{[2
]}

Reuss, J. ^{[2
]}

Ji, H. ^{[2
]}

Forde, P. M. ^{[2
]}

Pardoll, D. M. ^{[2
]}

Smith, K. N. ^{[2
]}

Szalay, A. S. ^{[2
]}

Taube, J. M. ^{[2
]}

Cottrell, T. R. ^{[1
]}

机构：

[1] Queens Univ, Kingston, ON, Canada

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Mem Sloan Kettering Canc Ctr, Middletown, NJ USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA09.04

引用

页码：S88 / S88

页数：1

共 50 条

[1] PD-1+ IFN-γ+ subset of CD8+ T cell in circulation predicts response to anti-PD-1 therapy in NSCLC
Chen, Wenxiu
Hua, Yiting
Shan, Conghui
Wei, Jia
Zhou, Yutong
Pan, Shiyang
FRONTIERS IN ONCOLOGY, 2023, 13
[2] Dynamics of CD8+T cell subsets correlated with clinical response to anti-PD-1 antibody
Kawakami, Yutaka
Ohta, Shigeki
CANCER SCIENCE, 2021, 112 : 964 - 964
[3] Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients
Kunert, Andre
Basak, Edwin A.
Hurkmans, Daan
Klaver, Yarne
van Brakel, Mandy
Oostvogels, Astrid
Lamers, Cor
Bins, Sander
Koolen, Stijn L. W.
Van Der Veldt, Astrid
Sleijfer, Stefan
Mathijssen, Ron H. J.
Aerts, Joachim G. J. V.
Debets, Reno
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Distinct CD4+T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC
Figueiredo, Amanda
Evangelista, Guilherme
Cavalcanti, Clara
Morais, Katia
Souza-Silva, Thaiany Goulart
Balderas, Robert
Lopes, Rodrigo Pestana
Santos e Silva, Juan
Avila, Jonathan
Nakaya, Helder
Galdino, Nayane
Kuil, Larissa Melo
Lopes, Ananda Domingues
Turner, James
Freitas, Helano
Gross, Jefferson Luiz
Dutra, Walderez O.
Lima, Valdemir
Gollob, Kenneth J.
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[5] A tumor draining lymph node CD8 T cell memory response is pivotal for a decrease in recurrence after neoadjuvant anti PD-1 therapy for NSCLC
Cruz, Tatiana Delgado
Markowitz, Geoffrey J.
Martin, Mitchell
Singh, Arshdeep
Bai, Shelley Yang
Altorki, Nasser
McGraw, Timothy
Mittal, Vivek
Villena-Vargas, Jonathan
CANCER RESEARCH, 2023, 83 (07)
[6] Serum-derived exosomal PD-L1 and tumor-infiltrating CD8+T cell expression for predicting anti-PD-1 response in NSCLC
Shimada, Yoshihisa
Matsubayashi, Jun
Kudo, Yujin
Ohira, Tatsuo
Ikeda, Norihiko
CANCER SCIENCE, 2021, 112 : 370 - 370
[7] High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients
Koh, J.
Hur, J. Y.
Lee, K. Y.
Kim, M. S.
Heo, J. Y.
Ku, B. M.
Sun, J.
Lee, S.
Ahn, J. S.
Park, K.
Ahn, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S544 - S544
[8] Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC)
Cottrell, Tricia R.
Stein, Julie E.
Chaft, Jamie E.
Thompson, Elizabeth D.
Rekhtman, Natasha
Anagnostou, Valsamo
Smith, Kellie N.
Duffield, Amy S.
Anders, Robert A.
Isbell, James M.
Jones, David R.
Cuda, Jonathan D.
Battafarano, Richard
Yang, Stephen C.
Illei, Peter B.
Gabrielson, Edward
Askin, Frederic
Velez, Moises
Hellmann, Matthew D.
Sauter, Jennifer L.
Danilova, Ludmila
Velculescu, Victor E.
Wolchok, Jedd D.
Topalian, Suzanne L.
Brahmer, Julie R.
Pardoll, Drew M.
Cimino-Mathews, Ashley
Forde, Patrick M.
Taube, Janis M.
CANCER RESEARCH, 2018, 78 (13)
[9] Increased CD3+T cells with a low FOXP3+/CD8+T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
Kim, Hyojin
Kwon, Hyun Jung
Han, Yeon Bi
Park, Soo Young
Kim, Eun Sun
Kim, Se Hyun
Kim, Yu Jung
Lee, Jong Seok
Chung, Jin-Haeng
MODERN PATHOLOGY, 2019, 32 (03) : 367 - 375
[10] Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 Therapy
Bortone, Dante S.
Woodcock, Mark G.
Parker, Joel S.
Vincent, Benjamin G.
CANCER IMMUNOLOGY RESEARCH, 2021, 9 (01) : 103 - 112

← 1 2 3 4 5 →